Role of chemokines in proteinuric kidney disorders

Expert Reviews in Molecular Medicine

Volumn 16, Issue , 2014, Pages

  Moreno, Juan Antonio ^a   Moreno, Sara ^b   Rubio Navarro, Alfonso ^a   Gómez Guerrero, Carmen ^a,d   Ortiz, Alberto ^a,c   Egido, Jesús ^a,c,d  

^a 28400 Madrid   (Spain)

^b INIA   (Spain)

^c Section of Nephrology   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BINDARIT; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; NOX E 36; PF 04634817; RS 504393; SPIEGELMER; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALPORT SYNDROME; CELL ACTIVITY; CELL INFILTRATION; CELL INTERACTION; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EXPERIMENTAL STUDY; EXPOSURE; GLOMERULAR FILTRATION BARRIER; GLOMERULONEPHRITIS; HEYMANN NEPHRITIS; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATORY CELL; INTOXICATION; INTRACELLULAR SIGNALING; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; LEUKOCYTE MIGRATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MICROALBUMINURIA; MOLECULAR MECHANICS; NEPHROSIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOAD; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; PROTEIN TRANSPORT; PROTEINURIA; REVIEW; ANIMAL; DIET THERAPY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; NEPHRITIS; PHYSIOLOGY;

ANIMALS; CHEMOKINES; GENE EXPRESSION REGULATION; HUMANS; NEPHRITIS; PROTEINURIA; RECEPTORS, CHEMOKINE;

EID: 84896480038     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2014.3     Document Type: Review

References (133)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 3, 1-150
2. Carroll, M.F. and Temte, J.L. (2000) Proteinuria in adults: a diagnostic approach. American Family Physician 62, 1333-1340
3. Reiser, J. et al. (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. Journal of Clinical Investigation 113, 1390-1397
4. D'Amico, G. and Bazzi, C. (2003) Pathophysiology of proteinuria. Kidney International 63, 809-825
5. Iseki, K. et al. (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney International 63, 1468-1474
6. Breyer, J.A. et al. (1996) Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney International 50, 1651-1658
7. Peterson, J.C. et al. (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Annals of Internal Medicine 123, 754-762
8. Irie, F. et al. (2006) The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney International 69, 1264-1271
9. Jafar, T.H. et al. (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine 135, 73-87
10. Jafar, T.H. et al. (2001) Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney International 60, 1131-1140
11. Menon, M.C., Chuang, P.Y. and He, C.J. (2012) The glomerular filtration barrier: components and crosstalk. International Journal of Nephrology 2012, 749010
12. Ruggenenti, P., Perna, A. and Remuzzi, G. (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney International 63, 2254-2261
13. Abbate, M. et al. (2002) Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney International 61, 2066-2077
14. Ohse, T. et al. (2006) Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells. Kidney International 70, 1447-1455
15. Tang, S. et al. (1999) Apical proteins stimulate complement synthesis by cultured human proximal tubular epithelial cells. Journal of American Society of Nephrology 10, 69-76
16. Zoja, C. et al. (1995) Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. American Journal of Kidney Diseases 26, 934-941
17. Anders, H.J. et al. (2003) CC chemokine ligand 5/ RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. Journal of Immunology 170, 5658-5666
18. Chung, A.C. and Lan, H.Y. (2011) Chemokines in renal injury. Journal of American Society of Nephrology 22, 802-809
19. Zoja, C. et al. (1998) Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney International 53, 1608-1615
20. Segerer, S., Nelson, P.J. and Schlondorff, D. (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. Journal of American Society of Nephrology 11, 152-176
21. Weber, K.S. et al. (1999) Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow. European Journal of Immunology 29, 700-712
22. Langer, H.F. and Chavakis, T. (2009) Leukocyteendothelial interactions in inflammation. Journal of Cellular and Molecular Medicine 13, 1211-1220
23. Imhof, B.A. and Aurrand-Lions, M.(2004) Adhesion mechanismsregulating themigration of monocytes. Nature Reviews Immunology 4, 432-444
24. Kuroiwa, T. et al. (2000) Distinct Tcell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. Journal of Immunology 164, 3323-3329
25. Sanz, A.B. et al. (2010) NF-kappaB in renal inflammation. Journal of American Society of Nephrology 21, 1254-1262
26. Mezzano, S. et al. (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrology Dialysis Transplantation 19, 2505-2512
27. Zlotnik, A. and Yoshie, O. (2000) Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127
28. Ansel, K.M. et al. (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309-314
29. Murphy, P.M. et al. (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews 52, 145-176
30. Moreno, J.A. et al. (2012) Targeting chemokines in proteinuria-induced renal disease. Expert Opinion on Therapeutic Targets 16, 833-845
31. Moore, B.B. et al. (1998) CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. Journal of Investigative Medicine 46, 113-120
32. Quackenbush, E.J. et al. (1997) Eotaxin influences the development of embryonic hematopoietic progenitors in the mouse. Journal of Leukocyte Biology 62, 661-666
33. Strieter, R.M. et al. (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry 270, 27348-27357
34. Wong, M.M. and Fish, E.N. (2003) Chemokines: attractive mediators of the immune response. Seminars in Immunology 15, 5-14
35. Mantovani, A. (1999) The chemokine system: redundancy for robust outputs. Immunology Today 20, 254-257
36. Schlondorff, D. et al. (1997) Chemokines and renal disease. Kidney International 51, 610-621
37. Tipping, P.G. and Holdsworth, S.R. (2007) Cytokines in glomerulonephritis. Seminars in Nephrology 27, 275-285
38. Yamagishi, S. et al. (2007) Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Current Drug Targets 8, 952-959
39. Jimenez-Sainz, M.C. et al. (2003) Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Molecular Pharmacology 64, 773-782
40. Takaya, K. et al. (2003) Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. American Journal of Physiology - Renal Physiology 284, F1037-F1045
41. Eddy, A.A. and Giachelli, C.M. (1995) Renal expression of genes that promote interstitial inflammation and fibrosis in rats with proteinoverload proteinuria. Kidney International 47, 1546-1557
42. Donadelli, R. et al. (2000) Protein traffic activates NF-kB gene signaling and promotes MCP-1- dependent interstitial inflammation. American Journal of Kidney Diseases 36, 1226-1241
43. Ou, Z.L., Natori, Y. and Natori, Y. (2000) Transient and sequential expression of chemokine mRNA in glomeruli in puromycin aminonucleoside nephrosis. Nephron 85, 254-257
44. Chow, F.Y. et al. (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney International 69, 73-80
45. Wu, H. et al. (2005) DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney International 67, 2178-2186
46. Yoshimoto, K. et al. (2004) CD68 and MCP-1/CCR2 expression of initial biopsies reflect the outcomes of membranous nephropathy. Nephron Clinical Practice 98, c25-c34
47. Wasilewska, A. et al. (2011) Urinary monocyte chemoattractant protein-1 excretion in children with glomerular proteinuria. Scandinavian Journal of Urology and Nephrology 45, 52-59
48. Lepenies et al. (2011) Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-beta(1) in patients with chronic kidney disease. Nephron Clinical Practice 119, c97-c104
49. El-Shehaby, A. et al. (2011) Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. Journal of Clinical Immunology 31, 848-856
50. Segerer, S. et al. (1999) Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney International 56, 52-64
51. Xie, C. et al. (2011) RANTES deficiency attenuates autoantibody-induced glomerulonephritis. Journal of Clinical Immunology 31, 128-135
52. Schadde, E. et al. (2000) Expression of chemokines and their receptors in nephrotoxic serum nephritis. Nephrology Dialysis Transplantation 15, 1046-1053
53. Wagrowska-Danilewicz, M., Danilewicz, M. and Stasikowska, O. (2005) CC chemokines and chemokine receptors in IgA nephropathy (IgAN) and in non-IgA mesangial proliferative glomerulonephritis (MesProGN). The immunohistochemical comparative study. Polish Journal of Pathology 56, 121-126
54. Anders, H.J. et al. (2001) Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. Journal of American Society of Nephrology 12, 919-931
55. Elmarakby, A.A. and Sullivan, J.C. (2012) Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovascular Therpeutics 30, 49-59
56. Tian, S. et al. (2007) Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflammation Research 56, 304-310
57. Pease, J.E. (2006) Asthma, allergy and chemokines. Current Drug Targets 7, 3-12
58. Pereira, R.L. et al. (2012) Invariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosis. PLoS One 7, e32454
59. Cook, D.N. et al. (2000) CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12, 495-503
60. Welsh-Bacic, D. et al. (2011) Expression of the chemokine receptor CCR6 in human renal inflammation. Nephrology Dialysis Transplantation 26, 1211-1220
61. Turner, J.E. et al. (2010) CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. Journal of American Society of Nephrology 21, 974-985
62. Villa, L. et al. (2013) Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms. Journal of Pathology. 229, 672-684
63. Segerer, S. et al. (2003) When renal allografts turn DARC. Transplantation 75, 1030-1034
64. Vielhauer, V. et al. (2009) Efficient renal recruitment of macrophages and Tcells in mice lacking the duffy antigen/receptor for chemokines. American Journal of Pathology 175, 119-131
65. Tang, S. et al. (2003) Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. Journal of Clinical Investigation 111, 515-527
66. Yokoyama, H. et al. (1998) Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. Journal of Leukocyte Biology 63, 493-499
67. Ni, J. et al. (2012) Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease. Chinese Medical Journal (Engl) 125, 1147-1152
68. Khajehdehi, P. et al. (2011) Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scandinavian Journal of Urology and Nephrology 45, 365-370
69. Wada, T. et al. (1994) Prevention of proteinuria by the administration of anti-interleukin 8 antibody in experimental acute immune complex-induced glomerulonephritis. Journal of Experimental Medicine 180, 1135-1140
70. Rovin, B.H. et al. (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. Journal of American Society of Nephrology 16, 467-473
71. Souto, M.F. et al. (2008) Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria. Pediatric Research 64, 637-642
72. Lee, E.Y., Lee, Z.H. and Song, Y.W. (2009) CXCL10 and autoimmune diseases. Autoimmunity Reviews 8, 379-383
73. Gomez-Chiarri, M. et al. (1996) Interferon-inducible protein-10 is highly expressed in rats with experimental nephrosis. American Journal of Pathology 148, 301-311
74. Han, G.D. et al. (2006) IFN-inducible protein-10 plays a pivotal role in maintaining slit-diaphragm function by regulating podocyte cell-cycle balance. Journal of American Society of Nephrology 17, 442-453
75. Avihingsanon, Y. et al. (2006) Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney International 69, 747-753
76. Lu, J. et al. (2011) Gene expression ofTWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology (Carlton) 16, 426-432
77. Wang, A. et al. (2009) CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. Journal of Immunology 182, 4448-4458
78. Sayyed, S.G. et al. (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor- 1/CXCL12,which contributes to glomerulosclerosis, podocyte loss and albuminuria in amouse model of type 2 diabetes. Diabetologia 52, 2445-2454
79. Gutwein, P. et al. (2009) CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. American Journal of Pathology 174, 2061-2072
80. Teramoto, K. et al. (2008) Microarray analysis of glomerular gene expression in murine lupus nephritis. Journal of Pharmacological Sciences 106, 56-67
81. Izquierdo, M.C. et al. (2012) TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney International 81, 1098-1107
82. Bazan, J.F. et al. (1997) A new class of membranebound chemokine with a CX3C motif. Nature 385, 640-644
83. Chakravorty, S.J. et al. (2002) Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion. Clinical and Experimental Immunology 129, 150-159
84. Donadelli, R. et al. (2003) Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogenactivated protein kinase-dependent pathways. Journal of American Society of Nephrology 14, 2436-2446
85. Segerer, S. et al. (2002) Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney International 62, 488-495
86. Furuichi, K. et al. (2001) Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 87, 314-320
87. Nakatani, K. et al. (2010) Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severityand diversity in lupus models. American Journal of Physiology - Renal Physiology 299, F207-F216
88. Feng, L. et al. (1999) Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney International 56, 612-620
89. Cockwell, P. et al. (2002) Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines. Nephrology Dialysis Transplantation 17, 734-744
90. Birn, H. et al. (2000) Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. Journal of Clinical Investigation 105, 1353-1361
91. Cui, S. et al. (1996) Megalin/gp330 mediates uptake of albumin in renal proximal tubule. American Journal of Physiology 271, F900-F907
92. Birn, H. and Christensen, E.I. (2006) Renal albumin absorption in physiology and pathology. Kidney International 69, 440-449
93. Baggiolini, M. (1998) Chemokines and leukocyte traffic. Nature 392, 565-568
94. Suzuki, Y. et al. (2001) Renal tubulointerstitial damage caused by persistent proteinuria is attenuatedinAT1-deficientmice:roleofendothelin-1. American Journal of Pathology 159, 1895-1904
95. Wang, Y. et al. (1997) Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. Journal of American Society of Nephrology 8, 1537-1545
96. Rangan, G.K. et al. (1999) Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney International 56, 118-134
97. Takase, O. et al. (2003) Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney International 63, 501-513
98. Morigi, M. et al. (2002) Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. Journal of American Society of Nephrology 13, 1179-1189
99. Nakajima, H. et al. (2004) Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells byalbumin. Journal of American Society of Nephrology 15, 276-285
100. Reich, H. et al. (2005) Albumin activates ERK via EGF receptor in human renal epithelial cells. Journal of American Society of Nephrology 16, 1266-1278
101. Milligan, G. (2001) Oligomerisation of G-proteincoupled receptors. Journal of Cell Science 114, 1265-1271
102. Mellado, M. et al. (2001) Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO Journal 20, 2497-2507
103. Rajagopal, R. et al. (2004) Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. Journal of Neuroscience 24, 6650-6658
104. Wenzel, U. et al. (1997) Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney International 51, 770-776
105. Fujinaka, H. et al. (1997) Suppression of antiglomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. Journal of American Society of Nephrology 8, 1174-1178
106. Wu, X. et al. (1994) Cytokine-induced neutrophil chemoattractant mediates neutrophil influx in immune complex glomerulonephritis in rat. Journal of Clinical Investigation 94, 337-344
107. Garcia, G.E. et al. (2003) Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. American Journal of Pathology 162, 1061-1073
108. Garcia, G.E. et al. (2007) Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibodyassociated glomerulonephritis. American Journal of Pathology 170, 1485-1496
109. Lee, E.Y. et al. (2009) The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. American Journal of Physiology - Renal Physiology 297, F85-F94
110. Kanamori, H. et al. (2007) Inhibition of MCP-1/ CCR2 pathway ameliorates the development of diabetic nephropathy. Biochemical and Biophysical Research Communications 360, 772-777
111. Kang, Y.S. et al. (2010) CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney International 78, 883-894
112. Panzer, U. et al. (1999) The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney International 56, 2107-2115
113. Chow, F. et al. (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney International 65, 116-128
114. Vielhauer, V. et al. (2004) CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney International 66, 2264-2278
115. Ninichuk, V. et al. (2005) Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. Journal of American Society of Nephrology 16, 977-985
116. Ding, M. et al. (2006) Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nature Medicine 12, 1081-1087
117. Inoue, A. et al. (2005) Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis and Rheumatology 52, 1522-1533
118. Laborde, E. et al. (2011) Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. Journal of Medical Chemistry 54, 1667-1681
119. Sakurai, H. et al. (1996) Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats. Biochimica et Biophysica Acta 1316, 132-138
120. Duthey, B. et al. (2010) Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Experimantal Dermatology 19, 661-666
121. Wan, Y. and Evans, R.M. (2010) Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. Journal of Molecular Endocrinology 44, 135-142
122. Hasegawa, H. et al. (2003) Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis and Rheumatology 48, 2555-2566
123. Kulkarni,O. et al.(2009)Anti-Ccl2 Spiegel merpermits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. Journal of Pharmacology and Experimental Therapeutics 328, 371-377
124. Plater-Zyberk, C. et al. (1997) Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunology Letters 57, 117-120
125. Matsui, M. et al. (2002) Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. Journal of Neuroimmunology 128, 16-22
126. Kothandan, G., Gadhe, C.G. and Cho, S.J. (2012) Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study. PLoS One 7, e32864
127. Zheng, C. et al. (2011) Discovery of INCB10820/ PF-4178903,apotent, selective,andorallybioavailable dual CCR2 and CCR5 antagonist. Bioorganic and Medicinal Chemistry Letters 21, 1442-1446
128. Reid, C. et al. (2006) Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody. Protein Engineering, Design and Selection 19, 317-324
129. Fagete, S. et al. (2009) Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent. MAbs 1, 288-296
130. Sapir, Y. et al. (2010) A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis. Journal of Immunology 185, 2589-2599
131. Scalley-Kim, M.L. et al. (2012)Anovel highly potent therapeutic antibody neutralizes multiple human chemokines and mimics viral immune modulation. PLoS One 7, e43332
132. Darisipudi, M.N. et al. (2011) Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. American Journal of Pathology 179, 116-124
133. Ble, A. et al. (2011) Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. American Journal of Nephrology 34, 367-372